The polyamine biosynthetic pathway has been targeted in anti-trypanosomal drug-therapies, in particular for the treatment of African sleeping sickness caused by Trypanosoma brucei, a parasite in the same genus as T. cruzi. α-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), can eradicate T. brucei infections in mice [12] and has been successfully deployed in the field for the treatment of African sleeping sickness [13–15]. This evidence concerns the gene ODC1 and human African trypanosomiasis.